According to the latest publicly available documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Revolution Medicines has officially demanded that Erasca immediately cease all research, development, and commercial promotion activities related to its anti-cancer drug Eras-0015 within the United States.

According to the latest publicly available documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Revolution Medicines has officially demanded that Erasca immediately cease all research, development, and commercial promotion activities related to its anti-cancer drug Eras-0015 within the United States.

老虎证券2026/04/27 12:44

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The document further reveals that Ge Ming Pharmaceutical has also requested Erasca to cease all comparative statements involving Eras-0015 and other drugs. This legal demand highlights a potential intellectual property conflict between the two companies in the field of tumor treatment. Currently, Erasca has not made a public response regarding this matter. The market is closely watching how this dispute may impact the progress of drug development for both parties and their performance in the capital markets.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Crypto prices